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5-10% of colorectal cancers are hereditary; there are 
two forms of predisposition: 1- familial adenomatous 
polyposis (FAP) is characterized by the presence of 
hundreds to thousands of adenomas, and is due to 
germline mutations of the APC gene on 5q21; 2- the 
hereditary nonpolyposis colorectal cancer (HNPCC, or 
Lynch syndrome) is due to germline mutations in genes 
intervening in the repair of DNA mismatches occuring 
during replication (mostly hMSH2 and hMLH1 on 
2p16 and 3p21 respectively). 
Epidemiology 
Third most frequent cancer in the world in both sexes; 
estimated world total of 572 000 new cases a year in 
1980; in developed countries, colorectal cancer ranks 
second (e.g.: 26 000 new cases each year in France). 
Clinics 
The majority of colorectal cancers arise from pre-
existing adenomatous polyps. 
Pathology 
Dukes's staging system, modified by Astler-Coller. 
Treatment 
Resection with adjuvant chemo and/or radiotherapy in 
higher stages. 
Prognosis 
Survival, although improving is not much more than 
50% after 5 years, depending mainly of the stage of 
tumour growth at the time of diagnosis; genetic 
alterations have been studied in relation to prognosis 
with contradictory results (loss of heterozygocity on




There are two types of colorectal cancers, according to 
the ploidy: 
- Aneuploid tumours showing numerous allelic losses; 
loss of heterozygosity (LOH) on chromosomes 17 and 
18 have been found in more than 75% of colorectal 
cancers; complete allelotyping showed that 
chromosome arms 1q, 4p, 5q, 6p, 6q, 8p, 9q, 18p and 
22q exhibited LOH in about 50% of the cases; 
- Diploid tumours without frequent allelic losses. 
Genes involved and Proteins 
Note: A number of genes are known to be implicated in 
tumour progression in colorectal cancers; they are 
either oncogenes or tumour suppressor genes; Fearon 
and Vogelstein proposed a model for the genetic basis 
of colorectal tumourigenesis. 
APC 
Location: 5q21-22 
DNA / RNA 
15 exons. 
Protein 
Tumour suppressor gene; the APC interacts with the 
adherens junction proteins a and beta-catenin 
suggesting involvement in cell adhesion; APC may also 
inhibit the transcription pathway regulated by the beta-
catenin/Tcf complex. 
Germinal mutations 
In familial adenomatous polyposis. 
Somatic mutations 
The APC gene is mutated in about 50% of sporadic 
colorectal tumours; most mutations are frameshifts o  
nonsense mutations resulting in premature stop codons; 
some mutations on beta-catenin have been described in 
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DNA / RNA 
11 exons. 
Protein 
Tumour suppressor; 5 highly-conserved regions 
containing a transactivation domain, a DNA-binding 
domain, nuclear localization signals and a 
tetramerization domain; P53 is thus a transcriptional 
regulator: guardian of the genome preventing cells 
from dividing before DNA damage is repaired. 
Somatic mutations 
Mutations of P53 are mostly located in exons 4 to 8 
with hotspots at codons 175, 245, 248, 273 and 282;
they can be either missense mutations, or non-sense, 
deletions, insertions and splicing mutations resulting in 
a truncated p53 protein. 
KRAS2 (or Ki-ras) 
Location: 12p12.1 
DNA / RNA 
3 exons. 
Protein 
Ki-ras belongs to the ras gene family containing also 
H-ras and N-ras; they encode for closely related 21-
kDa (189 amino acids) GTP-binding proteins with a 
role in growth signal transduction; oncogenes. 
Somatic mutations 
These genes are activated by point mutations at codons 
12, 13 and 61, and, in the case of colorectal cancers, 
Ki-ras is mutated on codons 12 or 13 in about 40% of 
the cases. 
There is incomplete data to implicate a gene(s) on 
chromosome 18; it could be DCC (Deleted in Colon 
Cancer), DPC4 (Deleted in Pancreatic Cancer) or/and 
JV18, a Mad-related gene thought to transduce signal  
from TGFbeta family members. 
Mismatch repair genes (MMR genes): 
hMSH2, hMLH1, hPMS1, hPMS2, GTBP 
(hMSH6), and hMSH3 (DUG) 
Location: 2p16 (hMSH2, GTBP), 2q31-33 (hPMS1), 
3p21 (hMLH1), 7p22 (GTBP), 5q (hMSH3) 
Protein 
The proteins encoded by these genes are human 
homologs of the E. Coli Mut HLS system; they are 
implicated in the reparation of mismatches due to err rs 
during DNA replication; the more visible consequenc 
of the defect in mismatch repair is the presence of 
additional alleles at microsatellite loci which are 
repeats of 1 to 5 nucleotides scatterred on the genom ; 
due to their repetitive structure, microsatellite are 
particularly prone to replication errors; microsatellite 
instability is the hallmark of the RER (Replication 
Error) or MSI (MicroSatellite Instability) phenotype 
characteristic of HNPCC tumours and of 15% of 
sporadic colorectal cancers. 
Germinal mutations 
In HNPCC (Lynch syndrome), most patients have 
germline mutations of either hMSH2 or hMLH1. 
To be noted 
- The RER+ sporadic colon cancers are mostly diploid, 
without LOH, with few mutations of p53 and APC and 
right-sided; they contain mutations in repetitive coding 
sequences of a number of genes such as the TGFbeta 
type II receptor, the receptor of the Insulin-like growth 
factor and the BAX gene implicated in apoptosis. 
- the RER- are polyploid, with LOH (5q, 17p, 18q), 
mutations in p53, and more often left-sided, they have a 
worse prognosis. 
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